title: Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTATATE PRRT: a report of two cases.
abstract: Two patients diagnosed with metastatic medullary thyroid carcinoma (MTC) were referred for peptide receptor radionuclide therapy (PRRT) with Lu-[DOTA,Tyr]octreotate (DOTATATE). Each patient was treated with 4 doses of Lu-DOTATATE given 2 months apart. One patient achieved stable disease for 10 months then chose to pursue surgery, and the other achieved stable disease for 9 months on imaging; however, calcitonin continued to rise. The use of Lu-DOTATATE PRRT therapy in the management of MTC warrants further research.
authors: From the Department of Diagnostic Imaging, Cross Cancer Institute, Edmonton, AB, Canada.
authors: William
authors: W
authors: Makis
authors: Karey
authors: K
authors: McCann
authors: Alexander J B
authors: AJ
authors: McEwan
mesh_terms: D000328:Adult; D000368:Aged; D018278:Carcinoma, Neuroendocrine; D005260:Female; D006801:Humans; D008297:Male; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000532:radiotherapy*
chemical_list: D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C447941:lutetium Lu 177 dotatate; D015282:Octreotide